A	B	C
1	Main
2		Brand Name	Votrient fka Neovastat, AE-941, GW786034
3		Generic Name	pazopanib
4			Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, monohydrochloride
5			5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide monohydrochloride
6		Mechanism	VEGF RTK. a potent and selective inhibitor of VEGFR-1, -2 and -3 tyrosine kinases
7		Economics	Sold to Novartis
8		IP	12/19/2021 Orange book 7105530 C.O.M. patent.
9		Timeline	US approval 10/09, EMEA approval 6/10, EMEA recommendation 2/19/10.
10		Clinical Trials
11			Phase III trial in RCC n=400 began March 2006, Data April 2009
12			9.2 months for pazopanib versus 4.2 months for placebo. HR=0.46.
13
14			Phase III trial in RCC vs Sutent n=876, began 8/08.
15
16			Phase III trial in inflammatory mBC Tykerb+-pazopanib. Began 11/07. n=320
17
18			Phase III trial in soft tissue sarcoma. N=255, began 9/08.
19
20			Phase II Tykerb+- pazopanib in metastatic cervical n=180
21
22			Phase II Tykerb+- pazopanib in mBC n=140
23
24			Phase II trial in multiple myeloma
25			http://www.clinicaltrials.gov/ct/show/NCT00256880?order=1
26
27			Phase 1 data at ASCO 2006 - combo with Tykerb
28			in a 63 patient study, 6 out of 6 patients with renal cell carcinoma had a clinical benefit
29			Tumor shrinkage and prolonged stable disease was also observed in a number of other cancer types, including gastrointestinal, neuroendocrine, lung, thyroid and sarcomas